Bio-Techne Corp

Company Profile

Bio-Techne Corp had its IPO on 1989-02-09 under the ticker symbol TECH.

The company operates in the Healthcare sector and Biotechnology industry. Bio-Techne Corp has a staff strength of 3,000 employees.

Stock update

Shares of Bio-Techne Corp opened at $30.09 at the start of the last trading session i.e. 2023-06-03.

The stocks traded within a range of $29.9 - $30.2, and closed at $29.93.

This is a -0.2% slip from the previous day's closing price.

A total volume of 4,326 shares were traded at the close of the day’s session.

In the last one week, shares of Bio-Techne Corp have slipped by -0.73%.

Bio-Techne Corp's Key Ratios

Bio-Techne Corp has a market cap of $12.86 billion, indicating a price to book ratio of 7.7815 and a price to sales ratio of 11.8254.

In the last 12-months Bio-Techne Corp’s revenue was $1.12 billion with a gross profit of $758.09 million and an EBITDA of $344.29 million. The EBITDA ratio measures Bio-Techne Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Bio-Techne Corp’s operating margin was 24.81% while its return on assets stood at 7.11% with a return of equity of 15.09%.

In Q1, Bio-Techne Corp’s quarterly earnings growth was a positive 16.2% while revenue growth was a positive 1.3%.

Bio-Techne Corp’s PE and PEG Ratio

Forward PE

42.1941

Trailing PE

48.625

PEG

1.1476

Its diluted EPS in the last 12-months stands at $1.68 per share while it has a forward price to earnings multiple of 42.1941 and a PEG multiple of 1.1476. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Bio-Techne Corp’s profitability.

Bio-Techne Corp stock is trading at a EV to sales ratio of 12.3173 and a EV to EBITDA ratio of 30.4276. Its price to sales ratio in the trailing 12-months stood at 11.8254.

Bio-Techne Corp stock pays annual dividends of $0.32 per share, indicating a yield of 0.39% and a payout ratio of 28.57%.

Balance sheet and cash flow metrics

Total Assets

$2.60 billion

Total Liabilities

$141.16 million

Operating Cash Flow

$-241096000.00

Capital Expenditure

$11.75 million

Dividend Payout Ratio

28.57%

Bio-Techne Corp ended 2023 with $2.60 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $2.60 billion while shareholder equity stood at $1.89 billion.

Bio-Techne Corp ended 2023 with $94.61 million in deferred long-term liabilities, $141.16 million in other current liabilities, 1573000.00 in common stock, $1.25 billion in retained earnings and $870.54 million in goodwill. Its cash balance stood at $127.28 million and cash and short-term investments were $157.20 million. The company’s total short-term debt was $10,723,000 while long-term debt stood at $370.00 million.

Bio-Techne Corp’s total current assets stands at $571.00 million while long-term investments were $0 and short-term investments were $29.92 million. Its net receivables were $216.42 million compared to accounts payable of $81.28 million and inventory worth $169.46 million.

In 2023, Bio-Techne Corp's operating cash flow was $-241096000.00 while its capital expenditure stood at $11.75 million.

Comparatively, Bio-Techne Corp paid $0.29 in dividends in 2023.

Other key metrics

Current Trading Price

$29.93

52-Week High

$98.5717

52-Week Low

$67.5376

Analyst Target Price

$101.2

Bio-Techne Corp stock is currently trading at $29.93 per share. It touched a 52-week high of $98.5717 and a 52-week low of $98.5717. Analysts tracking the stock have a 12-month average target price of $101.2.

Its 50-day moving average was $28.73 and 200-day moving average was $29.36 The short ratio stood at 2.48 indicating a short percent outstanding of 0%.

Around 89.2% of the company’s stock are held by insiders while 9650.7% are held by institutions.